First Eagle Investment Management LLC acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 116,609 shares of the medical device company’s stock, valued at approximately $4,613,000.
A number of other hedge funds also recently made changes to their positions in ATRC. Aster Capital Management DIFC Ltd lifted its holdings in shares of AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after acquiring an additional 538 shares during the period. Geneos Wealth Management Inc. bought a new position in AtriCure during the second quarter worth about $37,000. First Horizon Corp bought a new stake in shares of AtriCure in the 3rd quarter valued at approximately $42,000. Comerica Bank raised its holdings in shares of AtriCure by 121.1% in the 4th quarter. Comerica Bank now owns 2,213 shares of the medical device company’s stock worth $88,000 after buying an additional 1,212 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of AtriCure by 36.6% during the third quarter. CWM LLC now owns 2,587 shares of the medical device company’s stock valued at $91,000 after acquiring an additional 693 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.
Insider Activity
In other news, insider Vinayak Doraiswamy sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total transaction of $149,150.00. Following the transaction, the insider directly owned 96,875 shares in the company, valued at approximately $2,889,781.25. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.00% of the company’s stock.
AtriCure Stock Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical device company reported $0.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.07. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The business had revenue of $141.25 million for the quarter, compared to the consensus estimate of $139.75 million. During the same quarter in the prior year, the company earned ($0.14) EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. On average, equities research analysts predict that AtriCure, Inc. will post 0.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $54.00 target price on shares of AtriCure in a report on Wednesday, February 18th. Needham & Company LLC reissued a “buy” rating and set a $45.00 price target on shares of AtriCure in a report on Thursday, February 12th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research report on Wednesday, April 1st. Oppenheimer cut shares of AtriCure from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 18th. Finally, Citizens Jmp cut their target price on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.71.
Read Our Latest Research Report on ATRC
AtriCure Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Stories
- Five stocks we like better than AtriCure
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
